



SVC Members Conflict of Interest (COI) Disclosures Information as of January 2, 2020

To ensure that deliberations of the Scientific Registry of Transplant Recipients (SRTR) Visiting Committee (SVC) and any subcommittees do not constitute a conflict of interest (COI) for its members, the SRTR collects COI disclosures from voting and ex-officio members.

See below for questions asked and information disclosed. Disclosed information suggesting that an individual may have a potential conflict of interest regarding one or more aspects of his/her work for the SRTR will be evaluated to determine whether action is needed to manage, reduce, or eliminate the conflict. Actions taken may include exclusion of an individual from specific activities, projects, discussions, or votes; in some instances, a conflict may preclude an individual from working with the SRTR in any capacity.

Questions Asked

1. Please list any SRTR-relevant entity (e.g., business, association, society, group, etc.) in which you, your spouse or domestic partner, or any dependent child of yours is a director, officer, employee, partner, or scientific advisory board member. Time frame: Past 3 years or reasonably expected in next 12 months.
2. Please list any SRTR-relevant entity (e.g., business, association, society, group, etc.) in which you, your spouse or domestic partner, or any dependent child of yours has an ownership interest or other financial interest more than 5% of the entity's equity. E.g., stocks/stock options. You need not disclose interests in mutual funds, pensions, or other institutional investment funds whose investment policies are beyond your control. Time frame: Any time in the past 3 years or reasonably expected in next 12 months.
3. Please describe any SRTR-relevant consulting arrangement or other agreement to provide services for which you, your spouse or domestic partner, or any dependent child of yours has received in any of the past 3 years or reasonably expect to receive during the next 12 months.
4. Please describe any SRTR-relevant arrangement under which you, your spouse or domestic partner, or any dependent child of yours has received in personal payments, loans, or services (other than consulting fees). Time frame: Past 3 years or reasonably expected in next 12 months.
5. Please describe any other relationships or arrangements you wish to have reviewed to determine whether they may be perceived as potential conflicts of interest.

Information Disclosed (see next page)



Information Disclosed (Q1 = Question 1, Q2 = Question 2, etc.)

Member [committee; * = ex- officio]	Disclosure Date	Disclosure(s)
Chen, Jonathan	12-18-2019	None
*Dunne, Shannon	1-2-2020	None
Formica, Richard	1-2-2020	Q3. Novartis; Paid Consultant
*Glazier, Alexandra	12-19-2019	None
Knight, Richard	12-26-19	Q1. American Association of Kidney Patients, President; NIDDK, Member Advisory Council; Quality Insights ESRD Network 5, BOD Member Q3. Care DX, Paid Consultant
Logan, Brent	12-27-2019	None
Markmann, James	12-16-2019	Q1. eGenesis, Scientific Advisory Board; QihanBio, Scientific Advisory Board
Mohan, Sumit	12-11-2019	Q1. Kidney International Reports, Intl Soc of Nephrology, Deputy Editor; Angion Pharmaceuticals, Member of Scientific Advisory Board Q5. Data advisory committee, UNOS, Member; ASN quality committee, Member
Newell, Kenneth A.	12-26-2019	Q1. Scientific Advisory Boards—Veloxis; CSL Behring; Sanofi; Mallinckrott; ITB Med; Telaris Therapeutics; Angion Biomedica; Norvartis; Hansa Biopharma; Viela Bio
*Odim, Jonah	1-2-2020	None
Orlowski, Jeffrey	9-16-2019	Q1. Lifeshare Transplant Donor Services of OK, President/CEO; Lifeshare Foundation, President; OPTN Region 4 Association, Councilor; OPTN Board Member; OPTN, MPSC Member. Q3. NYU Langone Transplant Program, Consultant; Donor Network West, Paid Consultant
Pittman, James	9-26-2019	None
*Stewart, Darren E.	12-13-2019	None